gdactosemia gene (mothers of galactosemic children) experience impaired fecundity and earlier age at natural menopause. Design. Retrospective cohort study comparing experiences of mothers of galactosemicchildren with mothers of children with phenylketomuia (PKU). Data collection consisted of a structured telephone interview with sections on menstrual, reproductive and medical histories. Participants. One hundred three galactosemia carriers and 116 PKU carriers (mean age. 35.0 and 38.4 years, respectively), recruited from 38 metabolic disease clinics throughout the United States. Main outcome measures.Time-to-pregnancy (a measure of fecundity), menstrual cycle patterns and natural menopause.Results. No differWCCwas seen between carriers of the galactosemia and the PKU genein history of r 12months of unprotected intercourse without a pregnancy, physician-diagnosed infertility or amenorrhea lasting 26 weeks. The fecundity ratio, adjusting for age.and smoking before most recent pregnancy, was I. 17 (95% C.I. 0.85-1.61). By age 45. 1I% of gahrctosemiacarriers who had not had a hysterectomy reported a natural menopause compared with 4% of PKU carriers (risk difference 7.2%, 95% C.I. -12.7% to 27.1%).Conclusion. Fecundity and other measuresof fertility did not differ between mothers of gaiactoscmic children and mothers of children with PKU. Suggestionsof an earlier age at natural menopause can not be addressed definitively in this cohort becauseof the small number of participants who were currently age45 years or older but may warrant additional assessmentas the cohort ages.
CASE REPORTS OF INTEREST Recmentgradomcelltmoroftheovary37yearsafterhitial di8gme8asereportandre~oftkouterature
Hines J.F.; Khalifa MA.; Moore J.L.; Fine K.P.; Lage J.M.; Barnes W.A. USA GYNECOL ONCOL 199660/3 (484-488) Granulosa cell tumors of the ovary (GCTs) are uncommon neoplasms that are characterixed by late recurrence and high survival rates. A case of recurrent GCT presenting 37 years after initial diagnosis is reported with a review of the literature. This case.illuatratcs an example of a very late recurrence and emphasii the importance of the extended follow-up required for these patients.
of Gynecology & Obstetrics 54 (19%) 307-316
Ueda M.; Okamoto Y.; Ueki M. JPN GYNECOL ONCOL 19966013(480-483) Nerve sheathtumors of the retroperitoneum are infrequently reported. In this paper, a rare case of a benign pelvic retroperiton~ schwannomaarising in the right paracolpium is presented.Preoperatively, magnetic resonanceimaging revealcd a solid tumor beside the vaginal canal with a clear margin. The tumor could be completely resectedby the transvaginal appreach and was diagnosed as a benign schwannomaof the Antoni A type with palisade arrangement. The patient had no symptoms of motor or sensory disturbances after surgery. !3ebammc.admmaofulevuivr:rcaserepartandreviewoftbe litomtmre
Carlson J.W.; McGlennen R.C.; Gomex R.; Longbella C.; Carter J.; Carson L.F. USA GYNECOL ONCOL 19966013(489-491) Although sebaceous ghuids are prominent on the vulva, sebaceouscarcinomas of the vulva rarely occur. In fact there have been only two casesof sebaceouscarcinomas of the vulva reported in the literature. Eighty percent of vulvar cancers are squamous in origin with human papillomavirus (HPV) DNA detected in approximately 69% of these cancers. We present a third patient with sebaceouscarcinoma of the vulva and the first to our knowledge who has been analyzed for HPV DNA. The case report and a review of the literature are presented. ExtmskemImesenchymal -oftbelabiumm8jla, Lin J.; Yip K.M.H.; MaBidli N.; Chow L.T.C. HKG GYNECOL ONCOL 199660/3 (492-493) Extraskeletal mesenchymalchondrosarcoma is a rare tumor. It has been noted to occur most commonly in muscle and the central nervous system. It has never been reported to occur in the sof?tissuesof the anogenital region. We report the first such case,occurring in a 40-year-old woman who presented with a l-year history of a mass originating in the left labium majus. After extensive local resection and lymph node dissection she remains disease-freeafter 40 months of follow-up.